When does this change take effect?

This change is effective Dec 10, 2025.

CommercialCoverageLow impact

08.01.76d, Evinacumab-dgnb (Evkeeza®)

Q: Who is affected by this change?

This affects Independence Blue Cross Endocrinology, Cardiology, Internal Medicine, Family Medicine providers on Commercial plans.

Independence Blue Cross·Endocrinology, Cardiology, Internal Medicine +1 more·Pharmacy

Effective date

Dec 10, 2025

We identified it

Jun 19, 2026

Days to comply

—

Summary

IBX Commercial updated their pharmacy policy for Evinacumab-dgnb (Evkeeza®), a cholesterol-lowering medication. The policy reissue became effective December 10, 2025, but only summary information is available without specific billing or coverage details.

Action Required

Action needed

By December 10, 2025: Billing team should access the full policy details at the provided IBX URL to review any changes to coverage criteria, prior authorization requirements, or billing procedures for Evinacumab-dgnb (Evkeeza®) prescriptions for IBX Commercial patients.

Related policy hubs

Independence Blue Cross policies Endocrinology Cardiology Internal Medicine Family Medicine